BioSpace News Archive

Waters Corporation will webcast its Q4 2017 financial results conference call live on Tuesday, January 23rd at 8:00 a.m. eastern time.

Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon sent the following annual letter to his colleagues at Intrexon.

Cue Biopharma today announced the closing of its initial public offering of 8,820,710 shares of its common stock at a public offering price of $7.50 per share on December 27, 2017.

Under the agreement, Janssen will supply daratumumab for a recently added combination dosing cohort in Syros’ ongoing Phase 2 clinical trial of SY-1425, a first-in-class selective retinoic acid receptor alpha (RARα) agonist, in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

OLINVO is an investigational product for the management of moderate to severe acute pain.

LDS announces the filing of an enhanced provisional patent for the CannaStrips technology and two additional applications for CannaStrips trademark protection in the United Kingdom and European Union to complement the Company’s current Canadian trademark application.

In conjunction with the financing, Tony Yao, MD, PhD, a Partner at ArrowMark Partners, will join NexImmune’s Board of Directors.

RenalGuard Solutions today reported positive results from a first-in-man feasibility study focusing on a novel use of the RenalGuard System to manage fluids during diuretic therapy in congestive heart failure patients suffering from fluid overload.

Neogen today announced that all shares of its common stock will begin trading today on a “post-split” basis to reflect the company’s previously announced 4-for-3 stock split.

At closing of the agreement, $75 million in aggregate principal amount of the Senior Secured Notes were issued.